France· FR:65172663
RECARBRIO 500 mg/500 mg/250 mg, poudre pour solution pour perfusion
A medicinal product containing imipénem monohydraté + cilastatine sodique + rélébactam monohydraté, registered in France by MERCK SHARP & DOHME (PAYS-BAS).
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- IMIPÉNEM MONOHYDRATÉ + CILASTATINE SODIQUE + RÉLÉBACTAM MONOHYDRATÉ
- Manufacturer
- MERCK SHARP & DOHME (PAYS-BAS)
- Country
- France (FR)
- ATC code
- —
- Reimbursed
- No
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 1
- cip13340093020126825 flacon(s) en verre de 20 ml
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Imipénem monohydraté + cilastatine sodique + rélébactam monohydraté in 9 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- NorwayRecarbrioMerck Sharp & Dohme B.V. (1)
- SpainRECARBRIO 500 mg/500 mg/250 mg POLVO PARA SOLUCION PARA PERFUSIONMerck Sharp & Dohme B.V.
- FinlandRecarbrioMerck Sharp & Dohme B.V.
- United KingdomRecarbrio 500mg/500mg/250mg powder for solution for infusion vialsMerck Sharp & Dohme (UK) Ltd
- IrelandRecarbrio 500 mg/500 mg/250 mg powder for solution for infusionMerck Sharp & Dohme BV,
- NetherlandsRecarbrio 500 mg/500 mg/250 mg, poeder voor oplossing voor infusieMerck Sharp & Dohme B.V.
- SwedenRecarbrio 500 mg/500 mg/250 mg Pulver till infusionsvätska, lösningMerck Sharp & Dohme BV
- CzechiaRECARBRIOMerck Sharp & Dohme B.V., Haarlem
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Recarbrio
- Liechtenstein · Recarbrio
- Norway · Recarbrio
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/16afd120-6918-4f61-a729-d1fadd576e64 GET /v1/drugs/16afd120-6918-4f61-a729-d1fadd576e64?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "65172663",
"date_amm": "2020-02-13",
"type_amm": "Procédure centralisée",
"numero_ue": "EU/1/19/1420",
"substance": "IMIPÉNEM MONOHYDRATÉ + CILASTATINE SODIQUE + RÉLÉBACTAM MONOHYDRATÉ",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "poudre pour solution pour perfusion",
"voies_administration": "intraveineuse",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Non"
}See everything about imipénem monohydraté + cilastatine sodique + rélébactam monohydraté.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.